- Introduction
- Main contents
- List of tables
- List of figures
Description:
Vitamin industry hot topics in 2014:
-On 19 March, 2014, BASF released a statement that its citral production line in Germany plant suffered a fire and had to close down. BASF's total citral capacity accounts for more than 60% of the global capacity, thus the fire leads to the tight supply of citral and has a huge impact on the downstream of vitamin A, fragrance and flavor, vitamin E and other products. Though BASF's citral resumed production in April, domestic supply situation didn't change.
-On 11 July, 2014, DSM announced that it had reached an agreement to acquire Aland Nutraceutical Holding, Ltd., a leading producer of vitamin C in China. Through the acquisitions, DSM can further strengthen its status in vitamin C market and expand its domains all over the world of human nutrition and health care, animal nutrition and health care and personal care.
-On 29 September, 2014, Zhejiang Hangzhou Xinfu Pharmaceutical Co., Ltd. announced that Hefei Yifan Bio-Pharm Co., Ltd., a subsidiary of Xinfu Pharmaceutical, will merge with Hefei Yifan Pharmaceutical Co., Ltd., another subsidiary of Xinfu Pharmaceutical. After the completion of the merger, Yifan Bio-Pharm will continue to exist while Yifan Pharmaceutical will be dismissed and deregistered.
-On 5 Nov., 2014, Guangzhou Lonza (Nansha) Co., Ltd. launched a 15,000 t/a vitamin B3 (niacinamide) and formally put into operation, which further enlarged the production capacity of China's vitamin B3. It's estimated that there is a risk of excess capacity.
Purpose of report:
To clearly describe China's vitamin industry, CCM has collected lots of information in various ways. In this report, development situation of vitamin listed companies has been described in detail, including company profile, financial performance, product mix, market share, and investment opportunity.
What to report:
In this report, the 9 listed vitamin companies have been analyzed exhaustively from the following aspects:
-Revenue and net profit of the listed vitamin companies, 2009-2013;
-Main product structure of the listed vitamin companies by main business revenue, 2013;
-Revenue and gross profit margin of vitamin business of the listed vitamin companies, 2009-2013;
-Regional distribution of the listed vitamin companies by main business revenue, 2012 and 2013;
-Top 5 customers of the listed vitamin companies by total revenue, 2012 and 2013.
-R&D investment of the listed vitamin companies, 2012 and 2013
Forecasts:
In the next few years, the vitamin industry in China will continue to be promising. On the whole, it’s worth investing in it.
Main contents:
(The price of report chapters below is for single user license, please contact us if you want
to update to corporate license.)
List of tables:
Table No.
|
Table Title
|
Table 2.1-1
|
Basic information of listed vitamin companies in China
|
Table 2.2-1
|
Revenue of the 9 listed vitamin companies in China, 2012 and 2013
|
Table 2.3-1
|
Net profit of 9 listed vitamin companies in China, 2013
|
Table 2.4-1
|
Total assets of 9 listed vitamin companies in China, 2012 and 2013
|
Table 2.5-1
|
R&D investment of nine listed vitamin enterprises in China, 2012 and 2013
|
Table 3.1-1
|
Regional distribution of North China Pharmaceutical by main business revenue, 2012 and 2013
|
Table 3.1-2
|
Top 5 customers of North China Pharmaceutical by revenue, 2012 and 2013
|
Table 3.1-3
|
R&D investment of North China Pharmaceutical, 2012 and 2013
|
Table 3.2-1
|
Regional distribution of Zhejiang Medicine by main business revenue, 2012 and 2013
|
Table 3.2-2
|
Top 5 customers of Zhejiang Medicine by revenue, 2013
|
Table 3.2-3
|
R&D investment of Zhejiang Medicine, 2011-2013
|
Table 3.3-1
|
Regional distribution of NHU by main business revenue, 2012 and 2013
|
Table 3.3-2
|
Top 5 customers of NHU by revenue, 2012 and 2013
|
Table 3.3-3
|
R&D investment of NHU, 2011-2013
|
Table 3.4-1
|
Regional distribution of Northeast Pharmaceutical by main business revenue, 2012 and 2013
|
Table 3.4-2
|
Top 5 customers of Northeast Pharmaceutical by revenue, 2012 and 2013
|
Table 3.4-3
|
R&D investment of Northeast Pharmaceutical, 2012 and 2013
|
Table 3.5-1
|
Regional distribution of PKU HealthCare by main business revenue, 2012 and 2013
|
Table 3.5-2
|
Top 5 customers of PKU HealthCare by revenue, 2012 and 2013
|
Table 3.5-3
|
R&D investment of PKU HealthCare, 2012 and 2013
|
Table 3.6-1
|
Regional distribution of Brother Enterprises by main business revenue, 2012 and 2013
|
Table 3.6-2
|
Top 5 customers of Brother Enterprises by revenue, 2012 and 2013
|
Table 3.6-3
|
R&D investment of Brother Enterprises, 2012 and 2013
|
Table 3.7-1
|
Regional distribution of Xinfu Pharmaceutical by main business revenue, 2012 and 2013
|
Table 3.7-2
|
Top 5 customers of Xinfu Pharmaceutical by revenue, 2012 and 2013
|
Table 3.7-3
|
R&D investment of Xinfu Pharmaceutical, 2012 and 2013
|
Table 3.8-1
|
Regional distribution of Xiamen Kingdomway by main business revenue, 2012 and 2013
|
Table 3.8-2
|
Top 5 customers of Xiamen Kingdomway by revenue, 2012 and 2013
|
Table 3.8-3
|
R&D investment of Xiamen Kingdomway, 2011-2013
|
Table 3.9-1
|
Regional distribution of Guangji Pharmaceutical by main business revenue, 2012 and 2013
|
Table 3.9-2
|
Top 5 customers of Guangji Pharmaceutical by revenue, 2012 and 2013
|
Table 3.9-3
|
R&D investment of Guangji Pharmaceutical, 2012 and 2013
|
CCM Customized Service on Market Research
Do you want Import & Export Analysis, Financial Data, Cost Analysis, Supply Chain Research etc. ? We will customize the specific research for you, in case the services listed above does not meet your precise requirements. Our product and industry research in China’s agriculture, chemicals, food & ingredients and life science markets will comprehensively cover the business information, which is able to help you arrive at strategic and profitable business decisions.
Please directly contact
econtact@cnchemicals.com to specify your Market Research Requirement